Early prediction of long-term response to natalizumab in multiple sclerosis
Conclusions
Relapses and new MRI activity within the first year of starting natalizumab predict short-term outcomes, but not long-term disability outcomes. This requires further validation in other cohorts.
Source: Journal of Neurology, Neurosurgery and Psychiatry - Category: Neurosurgery Authors: Raffel, J., Gafson, A., Dahdaleh, S., Nicholas, R. Tags: Immunology (including allergy), Multiple sclerosis Thur 21, Parallel session 5: Therapeutics Source Type: research
More News: Allergy | Allergy & Immunology | Brain | Copaxone | Disability | Multiple Sclerosis | Neurology | Neurosurgery | Psychiatry | Tysabri